Royal Bank of Canada
PHAT icon

Royal Bank of Canada’s Phathom Pharmaceuticals PHAT Stock Holding History

Royal Bank of Canada’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Sell
2,258
-3,508
-61% -$40K ﹤0.01% 6235
2026
Q1 		$64K Sell
5,766
-16,788
-74% -$212K ﹤0.01% 5363
2025
Q4 		$374K Sell
22,554
-139,889
-86% -$2M ﹤0.01% 4371
2025
Q3 		$1.91M Buy
162,443
+4,502
+3% +$46.5K ﹤0.01% 3447
2025
Q2 		$1.52M Buy
157,941
+147,759
+1,451% +$818K ﹤0.01% 3541
2025
Q1 		$64K Sell
10,182
-1,405
-12% -$8.53K ﹤0.01% 5458
2024
Q4 		$94K Buy
11,587
+4,581
+65% +$56.7K ﹤0.01% 5372
2024
Q3 		$126K Buy
7,006
+2,753
+65% +$38.5K ﹤0.01% 5179
2024
Q2 		$44K Buy
4,253
+2,237
+111% +$23K ﹤0.01% 5718
2024
Q1 		$22K Sell
2,016
-8,416
-81% -$71.5K ﹤0.01% 5880
2023
Q4 		$94K Buy
10,432
+4,716
+83% +$40.6K ﹤0.01% 5658
2023
Q3 		$59K Buy
5,716
+3,214
+128% +$44.1K ﹤0.01% 5697
2023
Q2 		$36K Buy
2,502
+617
+33% +$7.11K ﹤0.01% 5934
2023
Q1 		$13K Sell
1,885
-2,254
-54% -$19.8K ﹤0.01% 6203
2022
Q4 		$46K Buy
4,139
+3,859
+1,378% +$39.8K ﹤0.01% 5938
2022
Q3 		$3K Buy
280
+150
+115% +$1.43K ﹤0.01% 6913
2022
Q2 		$1K Sell
130
-1,114
-90% -$11.5K ﹤0.01% 7175
2022
Q1 		$17K Sell
1,244
-3,203
-72% -$51.7K ﹤0.01% 6693
2021
Q4 		$87K Buy
4,447
+2,579
+138% +$60.7K ﹤0.01% 6034
2021
Q3 		$60K Buy
1,868
+481
+35% +$16K ﹤0.01% 6053
2021
Q2 		$47K Buy
1,387
+725
+110% +$26K ﹤0.01% 6083
2021
Q1 		$25K Buy
+662
New +$27.7K ﹤0.01% 6304
2020
Q4 		– Sell
-7
Closed – – 7232
2020
Q3 		$0 Sell
7
-13
-65% -$450 ﹤0.01% 6853
2020
Q2 		$1K Sell
20
-494
-96% -$19K ﹤0.01% 6467
2020
Q1 		$13K Sell
514
-179
-26% -$5.98K ﹤0.01% 5735
2019
Q4 		$22K Buy
+693
New +$17.4K ﹤0.01% 5818

Other funds holding PHAT

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NEA Management Company
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Royal Bank of Canada's PHAT Position: Q2 2026 in Review

Royal Bank of Canada reduced its Phathom Pharmaceuticals (PHAT) stake by 61% in Q2 2026, selling an estimated $40K and leaving 2,258 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #6235.

Royal Bank of Canada first reported a position in PHAT in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.91M in Q3 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Royal Bank of Canada held 2,258 shares of Phathom Pharmaceuticals worth $24K as of Q2 2026.
  • Royal Bank of Canada sold 3,508 Phathom Pharmaceuticals shares in Q2 2026, an estimated $40K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6235 holding.
  • Royal Bank of Canada first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • Royal Bank of Canada's Phathom Pharmaceuticals position peaked at $1.91M in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.